#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer
Click to read the study in The Lancet Oncology.
Tag: tamoxifen
#VisualAbstract: Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer
Most estrogen receptor (ER)-positive breast cancers can be classified as luminal A or luminal B subtype. It has been estimated ...
Quick Take: Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in post-menopausal patients with luminal A or luminal B breast cancer
Most estrogen receptor (ER)-positive breast cancers can be classified as luminal A or luminal B subtype. It has been estimated ...
Quick Take: Overall survival with ribociclib plus endocrine therapy in breast cancer
Hormone therapy is the standard of care for premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor2 ...
Anastrazole superior to tamoxifen for breast cancer treatment [Classics Series]
1. Postmenopausal women with advanced breast cancer randomized to anastrazole as first-line therapy experienced an increase in time to progression ...
The ATLAS trial: Duration of adjuvant tamoxifen in ER-positive breast cancer [Classics Series]
Image: PD 1. Among women with early ER-positive breast cancer, continuing adjuvant tamoxifen for 10 years versus stopping at 5 ...
USPSTF recommends chemoprevention for women at high risk for breast cancer
Image: PD 1. Among high-risk women, the chemopreventative medications tamoxifen and raloxifene reduced the incidence of invasive breast cancer and ...
